N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease - The African American Study of Kidney Disease and Hypertension (AASK)

被引:37
作者
Astor, B. C. [1 ,2 ]
Yi, S. [1 ]
Hiremath, L. [3 ]
Corbin, T. [4 ]
Pogue, V. [5 ]
Wilkening, B. [6 ]
Peterson, G. [7 ]
Lewis, J. [8 ]
Lash, J. P. [9 ]
Van Lente, F. [10 ,11 ]
Gassman, J. [12 ]
Wang, X. [12 ]
Bakris, G. [13 ]
Appel, L. J. [1 ,2 ]
Contreras, G. [14 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Epidemiol, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA
[3] Ohio State Univ, Dept Nephrol, Columbus, OH 43210 USA
[4] Univ Michigan, Dept Med, Div Internal Med, Ann Arbor, MI 48109 USA
[5] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Dept Med, New York, NY 10032 USA
[6] Emory Univ, Dept Med, Div Renal, Atlanta, GA 30322 USA
[7] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[8] Vanderbilt Univ, Div Nephrol, Nashville, TN USA
[9] Univ Illinois, Nephrol Sect, Chicago, IL USA
[10] Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA
[11] Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA
[12] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[13] Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA
[14] Univ Miami, Miller Sch Med, Dept Med, Div Nephrol & Hypertens, Miami, FL 33152 USA
关键词
cardiovascular diseases; heart failure; hypertension; renal; kidney; natriuretic peptides;
D O I
10.1161/CIRCULATIONAHA.107.724187
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Higher levels of N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) predict cardiovascular disease (CVD) in several disease states, but few data are available in patients with chronic kidney disease or in blacks. Methods and Results - The African American Study of Kidney Disease and Hypertension trial enrolled hypertensive blacks with a glomerular filtration rate of 20 to 65 mL . min(-1) . 1.73 m(-2) and no other identified cause of kidney disease. NT-proBNP was measured with a sandwich chemiluminescence immunoassay (coefficient of variation 2.9%) in 994 African American Study of Kidney Disease and Hypertension participants. NT-proBNP was categorized as undetectable, low, moderate, or high. Proteinuria was defined as 24-hour urinary protein - creatinine ratio >0.22. A total of 134 first CVD events (CVD death or hospitalization for coronary artery disease, heart failure, or stroke) occurred over a median of 4.3 years. Participants with high NT-proBNP were much more likely to have a CVD event than participants with undetectable NT-proBNP after adjustment (relative hazard 4.0 [95% confidence interval [CI] 2.1 to 7.6]). A doubling of NT-proBNP was associated with a relative hazard of 1.3 (95% CI 1.0 to 1.6) for coronary artery disease, 1.7 (95% CI 1.4 to 2.2) for heart failure, 1.1 (95% CI 0.9 to 1.4) for stroke, and 1.8 (95% CI 1.4 to 2.4) for CVD death. The association of NT-proBNP with CVD events was significantly stronger (P-interaction = 0.05) in participants with than in those without proteinuria. Higher NT-proBNP was not associated with renal disease progression. Conclusions - These results suggest that elevated NT-proBNP levels are associated with higher CVD risk among blacks with hypertensive kidney disease. This association may be stronger in individuals with significant proteinuria.
引用
收藏
页码:1685 / 1692
页数:8
相关论文
共 39 条
  • [1] Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death
    Apple, FS
    Murakami, MM
    Pearce, LA
    Herzog, CA
    [J]. CLINICAL CHEMISTRY, 2004, 50 (12) : 2279 - 2285
  • [2] Association of kidney function and hemoglobin with left ventricular morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) Study
    Astor, BC
    Arnett, DK
    Brown, A
    Coresh, J
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (05) : 836 - 845
  • [3] Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease
    Austin, Wendy J.
    Bhalla, Vikas
    Hernandez-Arce, Israel
    Isakson, Susan R.
    Beede, Jennifer
    Clopton, Paul
    Maisel, Alan S.
    Fitzgerald, Robert L.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (04) : 506 - 512
  • [4] N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease
    Bibbins-Domingo, Kirsten
    Gupta, Reena
    Na, Beeya
    Wu, Alan H. B.
    Schiller, Nelson B.
    Whooley, Mary A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02): : 169 - 176
  • [5] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [6] Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients
    Carr, SJ
    Bavanandan, S
    Fentum, B
    Ng, L
    [J]. CLINICAL SCIENCE, 2005, 109 (01) : 75 - 82
  • [7] Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies
    Codognotto, Marta
    Piccoli, Antonio
    Zaninotto, Martina
    Mion, Monica
    Plebani, Mario
    Vertolli, Ugo
    Tona, Francesco
    Ruzza, Luisa
    Barchita, Agata
    Boffa, Giovanni M.
    [J]. CLINICAL CHEMISTRY, 2007, 53 (12) : 2097 - 2104
  • [8] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311) : 995 - 1003
  • [9] N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis
    DeFilippi, CR
    Fink, JC
    Nass, CM
    Chen, HG
    Christenson, R
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (01) : 35 - 44
  • [10] Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK)
    Gassman, JJ
    Greene, T
    Wright, JT
    Agodoa, L
    Bakris, G
    Beck, GJ
    Douglas, J
    Jamerson, K
    Lewis, J
    Kutner, M
    Randall, OS
    Wang, SR
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07): : S154 - S165